Spriggs K, Leahy E, Weibel N, Barnes S
Allergy. 2024; 80(3):864-866.
PMID: 39264019
PMC: 11891408.
DOI: 10.1111/all.16319.
Martini M, Mauro M, Bignardi D, Bonadonna P, Braschi M, Emiliani F
Clin Exp Allergy. 2024; 54(12):996-998.
PMID: 38986677
PMC: 11629069.
DOI: 10.1111/cea.14540.
Rueff F, Bauer A, Becker S, Brehler R, Brockow K, Chaker A
Allergol Select. 2023; 7:154-190.
PMID: 37854067
PMC: 10580978.
DOI: 10.5414/ALX02430E.
Rostaher A, Fischer N, Vigani A, Steblaj B, Martini F, Brem S
Animals (Basel). 2023; 13(19).
PMID: 37835609
PMC: 10571593.
DOI: 10.3390/ani13193002.
Sahiner U, Giovannini M, Escribese M, Paoletti G, Heffler E, Lozano M
J Pers Med. 2023; 13(5).
PMID: 37241015
PMC: 10223594.
DOI: 10.3390/jpm13050845.
Patient's Adherence and Compliance and Quality of Life During/After VIT.
Incorvaia C, Heffler E, Peveri S, Pucciarini F, Canonica G, Ridolo E
Front Allergy. 2022; 3:886054.
PMID: 35836739
PMC: 9273771.
DOI: 10.3389/falgy.2022.886054.
Honey bee venom re-challenge during specific immunotherapy: prolonged cardio-pulmonary resuscitation allowed survival in a case of near fatal anaphylaxis.
Micaletto S, Ruetzler K, Bruesch M, Schmid-Grendelmeier P
Allergy Asthma Clin Immunol. 2022; 18(1):44.
PMID: 35655287
PMC: 9164337.
DOI: 10.1186/s13223-022-00687-x.
Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.
Eitel T, Zeiner K, Assmus K, Ackermann H, Zoeller N, Meissner M
World Allergy Organ J. 2021; 14(5):100536.
PMID: 33995819
PMC: 8085710.
DOI: 10.1016/j.waojou.2021.100536.
Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.
Adelmeyer J, Pickert J, Pfutzner W, Mobs C
Allergol Select. 2021; 5:57-66.
PMID: 33521509
PMC: 7841418.
DOI: 10.5414/ALX02175E.
Benefits and limitations of sting challenge in hymenoptera venom allergy.
Assmus K, Meissner M, Kaufmann R, Valesky E
Allergol Select. 2021; 5:45-50.
PMID: 33490858
PMC: 7814776.
DOI: 10.5414/ALX02148E.
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.
Blank S, Grosch J, Ollert M, Bilo M
Front Immunol. 2020; 11:579409.
PMID: 33193378
PMC: 7643016.
DOI: 10.3389/fimmu.2020.579409.
Clinical Utility of Rush Venom Immunotherapy: Current Status.
Gruzelle V, Mailhol C, Waters D, Guilleminault L
J Asthma Allergy. 2020; 13:1-10.
PMID: 32021308
PMC: 6954838.
DOI: 10.2147/JAA.S200917.
A safe and efficient 7-week immunotherapy protocol with aluminum hydroxide adsorbed vespid venom.
Schrautzer C, Arzt-Gradwohl L, Bokanovic D, Schwarz I, cerpes U, Koch L
Allergy. 2019; 75(3):678-680.
PMID: 31394011
PMC: 7078896.
DOI: 10.1111/all.14012.
Quality-of-life in insect venom allergy: validation of the Turkish version of the "Vespid Allergy Quality of Life Questionnaire" (VQLQ-T).
Sin B, Oztuna D, Gelincik A, Gurlek F, Baysan A, Sin A
Springerplus. 2016; 5:583.
PMID: 27247880
PMC: 4864742.
DOI: 10.1186/s40064-016-2246-x.
Stinging insect allergy: current perspectives on venom immunotherapy.
Ludman S, Boyle R
J Asthma Allergy. 2015; 8:75-86.
PMID: 26229493
PMC: 4517515.
DOI: 10.2147/JAA.S62288.
[Sting challenge: indications and execution].
Rueff F, Przybilla B
Hautarzt. 2014; 65(9):796-801.
PMID: 25234628
DOI: 10.1007/s00105-014-2779-2.
